Operational Technologies Corporation

Judson C Miner

John G Bruno

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3' conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3&#x2032; A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3&#x2032; conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3&#x2032; conjugate.

Therapeutic nucleic acid-3'-conjugates

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3' conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3&#x2032; A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3&#x2032;-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate.

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3' conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3&#x2032; A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3&#x2032;-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate. For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3&#x2032;-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

Growing community of inventors

San Antonio, TX, United States of America

Judson C Miner